What changed
$REGN — WATCHLIST 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $3.6B | EPS $9.47 vs $8.90 🟢 | Margin 17.8%
💡 Consensus expected EPS of $8.90, actual $9.47. The beat may signal stronger underlying growth, but market-implied expectations are likely still cautious due to sector headwinds. My variant view expects positive estimate revisions, but this is unconfirmed and faces strong negative sector momentum.
📉 Reward/risk: 1.6:1
🏢 Business Quality: 8/10 - Leading biotech with strong R&D and blockbuster history, but facing patent cliffs and sector rotation risks.
📊 Valuation: fair - P/E 14.9x is at the top of its tight historical range (14.7-14.9x), not a discount relative to own history.
🔮 Catalyst: Analyst estimate revisions upward post-earnings
💰 Entry: $609.94, stop $580, target $660
📊 Our read: WATCHLIST. Full analysis →
https://stockduty.xyz/s/REGN0622